

## **Changing Paradigms in Acute Kidney Injury:** From Mechanisms to Management

UAB/UCSD O'Brien Center Symposium on AKI Tuesday, February 14, 2012 Hilton San Diego Bayfront

San Diego, California

Room: Aqua 306 AB

	AGENDA	
7:55 am	Opening Remarks Ravindra Mehta, MD	
PLENARY 1	Molecules, Mechanisms and Targets Co-Chairs: Bruce Molitoris, MD and Anupam Agarwal, MD	
8:00-8:20	The Pathogenesis of Acute Kidney Injury (AKI) & the Toxic Triangle of O2, NO & ROS - Can Ince, PhD	
8:20-8:40	Mitochondria Dynamics in AKI - Zheng Dong, PhD	
8:40-9:00	Sepsis and AKI: What Have We Learned? - Martin Matejovic, MD	
9:00-9:20	Cell Cycle Regulation in AKI - Robert Safirstein, MD	
9:20-9:40	Is Renal Dysfunction of Cirrhosis Truly Reversible? - Rajiv Jalan, MD	
9:40-10:00	Mechanisms of Repair After AKI - Ben Humphreys, MD	
10:00-10:15	Coffee Break	
PLENARY 2	Translational Research: Bedside to Bench and Back Co-Chairs: Robert Schrier & John Kellum	
10:15-10:35	Immune Hyporesponsiveness: Target for Monitoring and Intervention? - Didier Payen, MD	
10:35-10:55	Human Endotoxemia: Does it Lead to Tubular Injury? - Peter Pickkers, MD	
10:55-11:15	Acute Kidney Injury in Sepsis: A Role of the Microcirculation? - Daniel De Backer, MD	
11:15-11:35	Targeting Nrf2 Regulation of Oxidative Stress to Improve AKI - Hamid Rabb, MD	
11:35- 11:55	Targeting Recovery: What's Needed? - Ravindra Mehta, MD	
11:55-12:15	Utilizing Mechanistic Modeling to Facilitate Clinical Drug Development - William Macias, MD	
12:15-1:15 pm	Lunch Hosted by Conference for Workshop Participants	
PLENARY 3	Concurrent Sessions	
	A. Pre-Clinical Models for Translational Research in AKI	B. Enhancing Clinical and Translational Research in AKI
	Co-Chairs: Paul Sanders and Roland Blantz	Co-Chairs: Claudio Ronco and Robert Safirstein
1:15-1:35	Rodent Models and Imaging	When Did AKI Start: Baseline vs Reference Creatinine - Etienne Macedo, MD
1:35-1:55	Kurt Zinn, PhD  Dissecting Immune Responses in AKI	Clinical Endpoints for AKI: Do We
1.55 1.55	Mark Okusa, MD	Have a Consensus? - John Kellum, MD
1:55-2:15	Unraveling the Interactions of AKI and CKD	Outcomes Research: The Role of an
2.15.2.25	Roland C. Blantz, MD	AKI Registry - Josee Bouchard, MD
2:15-2:35	Visualizing the Microcirculation Bruce Molitoris, MD	Design Issues & Strategies for Biomarker Guided Clinical Trials - Zoltan Endre, MD
2:35-2:55	Using Gene-targeted Mice to Study Renal	Post-Cardiac Arrest Therapeutic Hypothermia
	Physiology In Vivo - Volker Vallon, MD	and Acute Kidney Injury - Henry Wang, MD
2:55-3:15	<b>Genetic Labeling Techniques</b>	Trial Designs for Preventing AKI Progression
	Ben Humphreys, MD	to CKD - Lakhmir Chawla, MD
3:15-3:30	Coffee Break	
PLENARY 4	Tools to Characterize Human AKI Co-Chairs: Mark Okusa and Hamid Rabb	
3:30-3:50	Epigenetics and the Interface Between Host and Environment - Andrew D. Shaw, MD FRCA	
3:50-4:10	Diagnostic Value of Urine Electrolytes in AKI - Robert Schrier MD	
4:10-4:30	Candidate Biomarkers for Sepsis Associated AKI in Children: A Microarray Analysis - Hector Wong, MD	
4:30-4:50	Biomarkers in AKI: An Update - Jonathan Barasch, MD PhD	
4:50-5:10	Assessing Kidney Function in the Patient with Cardiorenal Syndrome - Claudio Ronco, MD	
5:10-5:30	Urinary Exosomes: Emerging Tools for Characterizing AKI - Pam Taub, MD	
5:30	Adjourn	